SEC Tracker
Get the app
IMVT · XBRL financial data

Immunovant financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (IMVT's year ends in late March)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
General and administrative141315*19182020*26181517*18
Total operating expenses626281*94116114114*127132114160*160
Other income (expense)01(3)*01(1)1*10(0)1*0
Income tax expense (benefit)0(0)0*0001*112(3)*0
Net income (loss)(59)(51)(75)*(87)(109)(111)(106)*(121)(127)(111)(148)*(153)
Earnings per share, basic USD per share(0.45)(0.36)(0.52)*(0.60)(0.74)(0.76)(0.64)*(0.71)(0.73)(0.61)(0.72)*(0.75)
Earnings per share, diluted USD per share(0.45)(0.36)(0.52)*(0.60)(0.74)(0.76)(0.64)*(0.71)(0.73)(0.61)(0.72)*(0.75)
Weighted average shares, basic millions of shares131145146*146146147167*171174182204*206
Weighted average shares, diluted millions of shares131145146*146146147167*171174182204*206

Balance sheet

CSV

Fiscal quarters (IMVT's year ends in late March)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents270691635560473375714599522995902798
Accounts receivable115222222211
Total current assets2917116665895074137686525741,043949851
Property and equipment, net000111111100
Right-of-use asset1000000———0—
Total assets2927116665905164217766615831,052957852
Accounts payable84711212018879810
Accrued liabilities32284134464851———97—
Total current liabilities40324945676869536366104117
Lease liability, non-current000—————————
Total liabilities40324945676869536366104117
Accumulated deficit(699)(750)(826)(913)(1,022)(1,133)(1,240)(1,360)(1,487)(1,597)(1,745)(1,898)
Total stockholders' equity252679618545449353707609520986853735
Total liabilities and equity2927116665905164217766615831,052957852
Common shares outstanding (cover page) millions of shares145145146146147170171174175204205207

Cash flows

CSV

Fiscal quarters (IMVT's year ends in late March)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(59)(51)(75)*(87)(109)(111)(106)*(121)(127)(111)(148)*(153)
Stock-based compensation11*10*10*1313*12*12*1913*13*11*14
Net cash from operating activities(60)*(47)*(60)*(76)(89)*(100)*(111)*(117)(103)*(92)*(95)*(124)
Purchases of property and equipment0*0*0*00*0*0*00*0*0*—
Net cash from investing activities(0)*(0)*(0)*(0)(0)*(0)*(0)*00*0*(0)*—
Proceeds from issuing common stock——year only———450*———0*—
Net cash from financing activities0*470*2*11*2*451*325*565*4*20
Net change in cash(60)*421*(56)*(75)(87)*(98)*339*(115)(77)*473*(92)*(104)

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Immunovant798not reported(124)206.6M6.4 quarters 10-QJun 30, 2026
Innoviva58110642*71.1M— 10-QSep 30, 2026
Ani Pharmaceuticals42129184*not reported— 10-QSep 30, 2026
Celldex Therapeutics27not reported(65)*78.5M10.0 quarters 10-QSep 30, 2026
Travere Therapeutics12422598*96.0M— 10-QSep 30, 2026
Adaptive Biotechnologies76849.6*161.9M— 10-QSep 30, 2026
Mannkind41102(35)*321.6M4.2 quarters 10-QSep 30, 2026
Schrodinger24764(48)*not reported10.9 quarters 10-QSep 30, 2026
Arrowhead Pharmaceuticals5575(177)*141.3M9.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.